Brain Clearance Architecture: Supplement Proposals
These proposals extend the brain clearance architecture framework of Chayama et al. (2026) (Chayama et al. 2026) into nutraceutical support for perivascular structure, vasomotion, BBB integrity, AQP4 function, and border immune niche preservation.
For patients: little direct clinical use — each proposal is a hypothesis, not a recommendation; the CoQ10, magnesium L-threonate, and quercetin proposals overlap with the general supplement guidance in Chapter Supplements and Nutraceuticals.
For caregivers: little direct use; these proposals add no actionable protocol for supporting a patient at home.
For clinicians: read the proposals as research hypotheses for perivascular structure, vasomotion, BBB integrity, and AQP4 function — do not prescribe on this chapter alone.
For researchers: this is the primary audience — each proposal extends the Chayama brain-clearance architecture into a specific nutraceutical with a stated mechanism and testable prediction.
Certainty: 0.35. Perivascular basement membrane thickening and abnormal collagen deposition are documented consequences of chronic glymphatic impairment (Section Glymphatic Dysfunction and Brain Waste Accumulation). Vitamin C is an essential cofactor for prolyl hydroxylase and lysyl hydroxylase, enzymes required for proper collagen crosslinking. At adequate doses, vitamin C may support repair of abnormal perivascular basement membrane architecture, improving perivascular compliance and clearance route integrity.
Rationale. Chayama et al. demonstrate that perivascular spaces are the conduits for brain-derived protein clearance (Chayama et al. 2026). Chronic structural degradation of these spaces (70x recovery timescale, Section Glymphatic Dysfunction and Brain Waste Accumulation) implies that collagen repair is a rate-limiting step in clearance restoration. Vitamin C supports the enzymatic machinery for this repair.
- Dose: 500–1000 mg daily (divided doses, to maximize absorption)
- Safety: Very safe. Kidney stone risk at sustained doses above 2000 mg/day. Iron overload in hemochromatosis patients. Split dosing reduces GI upset.
- ME/CFS relevance: Vitamin C status in ME/CFS is not systematically studied. Collagen support is mechanistically plausible but entirely untested for glymphatic outcomes.
- Falsifiable. ME/CFS patients with documented perivascular basement membrane abnormalities (reduced compliance on MR-AIV) will show progressive perivascular compliance improvement over 12 months of vitamin C (1000 mg/day), with DTI-ALPS improvement exceeding 10 percent compared to placebo.
Certainty: 0.32. NE oscillations drive vasomotion via calcium signaling in vascular smooth muscle (Hauglund 2025, Section Neuronal Protein Tracing Reveals Physiological Brain Clearance Architecture). Magnesium modulates calcium channels and NMDA receptor function. Magnesium L-threonate crosses the blood-brain barrier, unlike other magnesium salts. By supporting calcium homeostasis in vascular smooth muscle and reducing NMDA-mediated excitotoxicity, magnesium L-threonate could enhance vasomotion amplitude — the primary pump driving glymphatic clearance through the fast advective pathway identified by Toscano 2026.
Rationale. Chayama et al. show that the skull and dural compartments are the primary clearance routes for brain-derived proteins (Chayama et al. 2026). Vasomotion (LC-NE oscillation-driven) is the pump that moves proteins through these compartments. Magnesium’s calcium-modulating properties may support this pump.
- Dose: 1–2 g magnesium L-threonate daily (providing 144–288 mg elemental magnesium)
- Safety: Very safe. Diarrhea at high doses (less common with L-threonate than other forms). Monitor renal function in patients with kidney disease.
- ME/CFS relevance: Magnesium deficiency is documented in ME/CFS subsets. Vasomotion support is mechanistically plausible, entirely untested, and represents an extension beyond the established use of magnesium for muscle cramps/pain.
- Falsifiable. ME/CFS patients will show improved vasomotion amplitude on MR-AIV (exceeding 15 percent increase) after 8 weeks of magnesium L-threonate (2 g/day), with corresponding DTI-ALPS improvement and reduced brain fog severity.
Certainty: 0.38. Glymphatic clearance must match metabolic waste generation. ME/CFS involves mitochondrial dysfunction (Chapter Energy Metabolism and Mitochondrial Function) that increases metabolic waste production per unit of neuronal activity. CoQ10 enhances mitochondrial electron transport efficiency, reducing electron leakage and ROS generation, thereby decreasing the waste load that the impaired glymphatic system must handle. This addresses the generation side of the generation-clearance imbalance. Chayama et al. (Chayama et al. 2026) demonstrate that clearance capacity is compartmentalized and finite — reducing waste generation at source is a complementary strategy to enhancing clearance.
- Dose: 300–600 mg daily (ubiquinol form for superior absorption)
- Safety: Very safe. GI upset possible. Potential interaction with warfarin (monitor INR).
- ME/CFS relevance: CoQ10+NADH RCT showed significant fatigue improvement in ME/CFS. The glymphatic mechanism is an additional mechanistic rationale beyond mitochondrial ATP support.
- Falsifiable. ME/CFS patients will show reduced CSF tau accumulation markers after 12 weeks of CoQ10 (600 mg/day ubiquinol), with DTI-ALPS improvement reflecting reduced clearance burden rather than directly enhanced clearance. Distinguishable from clearance-enhancing interventions (DORA, trazodone) by the absence of increased SWS or vasomotion amplitude.
Certainty: 0.28. Chayama et al. demonstrated that inflammation shunts brain-derived proteins into the bloodstream via vascular leakage, bypassing normal tolerogenic border clearance routes (Chayama et al. 2026). Quercetin stabilizes endothelial tight junctions and reduces vascular permeability through PI3K/Akt and NF-kB pathway modulation. Additionally, quercetin stabilizes mast cells. By reducing BBB permeability, quercetin could prevent the inflammatory rerouting of neuronal proteins into systemic circulation, preserving skull border tolerogenic function.
- Dose: 500 mg twice daily (with food; divided dosing improves bioavailability)
- Safety: Very safe. Drug interactions: may inhibit CYP3A4 (antibiotics, cyclosporine). Rare kidney toxicity at very high doses (above 1000 mg/day chronically). Generally well-tolerated.
- ME/CFS relevance: Quercetin is commonly used in ME/CFS for mast cell stabilization. BBB permeability normalization and routing protection are additional mechanistic rationales, entirely untested.
- Falsifiable. ME/CFS patients taking quercetin (500 mg BID) during acute inflammatory triggers (viral infection) will show reduced plasma CNS protein leakage (NfL less than 1.5x baseline) compared to placebo (predicted greater than 3x baseline), with corresponding reduced PEM severity.
Certainty: 0.30. Chayama et al. identified skull-resident B cells that maintain tolerogenic surveillance of brain-derived antigens (Chayama et al. 2026). Chronic neuroinflammation may disrupt this tolerogenic checkpoint (Section Skull Border B Cell Failure and CNS-Directed Autoimmunity in ME/CFS). Curcumin, a potent NF-kB inhibitor that crosses the blood-brain barrier, could reduce skull and meningeal inflammation, preserving tolerogenic B cell function and compartmental clearance integrity.
- Dose: 500 mg curcuminoids twice daily (Meriva, Theracurmin, or Longvida formulation required for bioavailability; standard curcumin has negligible absorption)
- Safety: Very safe. GI upset common. Blood thinning at high doses (avoid with anticoagulants). Gallbladder contraindication (bile flow stimulation).
- ME/CFS relevance: Curcumin’s anti-inflammatory effects are well-established in chronic inflammatory conditions. Border niche immune support is a novel mechanistic rationale, entirely untested.
- Falsifiable. ME/CFS patients with elevated autoantibodies taking bioavailable curcumin (500 mg BID) for 16 weeks will show reduced autoantibody titers and normalized border niche kinetics (prolonged antigen residence time approaching control values) on compartmental clearance imaging, with corresponding symptom improvement.
Certainty: 0.28. AQP4 water channel expression at astrocytic endfeet is regulated by SIRT1, an NAD+-dependent deacetylase. Resveratrol activates SIRT1. Chayama et al. (Chayama et al. 2026) show that AQP4-rich perivascular spaces are the conduits for brain clearance. Upregulating AQP4 expression via SIRT1 activation could enhance the osmotic gradient driving CSF-ISF exchange, particularly the slow diffusive component of glymphatic transport (Toscano 2026).
- Dose: 250–500 mg daily (trans-resveratrol, micronized or liposomal formulation for bioavailability)
- Safety: Very safe. Drug interactions: may potentiate warfarin (CYP inhibition). GI upset at high doses. Bioavailability is the primary limitation (standard resveratrol has negligible oral bioavailability; reformulated versions required).
- Falsifiable. ME/CFS patients will show increased estimated AQP4-mediated permeability on MR-AIV after 12 weeks of resveratrol (500 mg/day, bioavailable formulation), with corresponding DTI-ALPS improvement and reduced brain fog severity.